Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alcon ( (CH:ALC) ) has issued an announcement.
On May 28, 2025, Alcon announced that the U.S. Food and Drug Administration (FDA) approved TRYPTYR (acoltremon ophthalmic solution) 0.003% for treating Dry Eye Disease (DED). TRYPTYR is a first-in-class TRPM8 receptor agonist that stimulates natural tear production, offering a rapid and effective treatment option for DED, a condition affecting approximately 38 million individuals in the U.S. This approval marks a significant milestone for Alcon as it is their first prescription pharmaceutical treatment approved since becoming an independent, publicly traded company. The approval is based on successful Phase 3 trials, and Alcon plans to launch TRYPTYR in the U.S. in the third quarter of 2025, with future plans for global distribution.
The most recent analyst rating on (CH:ALC) stock is a Buy with a CHF98.07 price target. To see the full list of analyst forecasts on Alcon stock, see the CH:ALC Stock Forecast page.
More about Alcon
Alcon is a global leader in eye care, dedicated to helping people see brilliantly. With a heritage spanning over 75 years, Alcon offers a broad portfolio of products to enhance sight and improve lives, including surgical and vision care products. The company serves more than 260 million people in over 140 countries each year, addressing conditions such as cataracts, glaucoma, retinal diseases, and refractive errors.
Average Trading Volume: 1,144,235
Current Market Cap: CHF35.96B
Learn more about ALC stock on TipRanks’ Stock Analysis page.